Best Endometrial Cancer Hospital in Hyderabad - 11 Centres, NCCN Protocols, NABH-Accredited Partners

No single hospital is automatically best — and for endometrial cancer, the most important factors are whether the surgical team is led by a gynaecologic oncologist (a women’s cancer specialist, distinct from a general gynaecologist), whether the hospital offers minimally invasive (laparoscopic or robotic) hysterectomy where appropriate, and whether Lynch syndrome screening is done on every case. CION Cancer Clinics meets these criteria with 11 centres across Hyderabad and 1,000+ endometrial cancer cases managed every year.

Verify eight things in writing: a gynaecologic oncology-led team, tumour-board review with risk-stratified planning, annual hysterectomy and minimally invasive surgery volume, MRI and endometrial biopsy and Lynch syndrome testing infrastructure, adjuvant radiotherapy access including vaginal brachytherapy, NABH-accredited partners for hysterectomy and minimally invasive surgery, insurance and Aarogyasri empanelment, and continuity of care including Lynch syndrome genetic counselling, survivorship, and hormone management.

No — most postmenopausal bleeding is not cancer. Common causes include thinning of the uterine lining, hormone changes, fibroids, or polyps. But about 10–15% of women with postmenopausal bleeding turn out to have endometrial cancer or pre-cancer — and that’s why every episode of postmenopausal bleeding (any bleeding after menopause) needs evaluation. The first investigation is a transvaginal ultrasound, which takes a few minutes. If the uterine lining is thicker than expected, an endometrial biopsy follows — often done as an office procedure. The reason this matters so much: catching endometrial cancer at the localised stage results in cure rates above 95%.

Endometrial cancer outcomes are among the better outcomes in gynaecologic oncology because most cases are caught early. Per US National Cancer Institute SEER data, 5-year relative survival is approximately 95% for localised disease (caught while still confined to the uterus), 70% for regional spread, and 18% for distant spread — with an overall average of about 84% across all stages. The hospital you choose directly affects whether you receive complete modern treatment including appropriate surgery, risk-stratified adjuvant therapy, and Lynch syndrome screening that may matter for your family. See our endometrial cancer treatment overview for more detail.

Costs vary by stage and treatment intensity. Indicative ranges: transvaginal ultrasound ₹1,000–3,000; endometrial biopsy ₹5,000–12,000; hysteroscopy with biopsy ₹15,000–30,000; MRI pelvis ₹6,000–12,000; total hysterectomy with removal of ovaries and tubes ₹2–5 lakh; laparoscopic or robotic hysterectomy ₹3.5–7 lakh via NABH-accredited partner; vaginal brachytherapy ₹50,000–1.5 lakh; external beam radiation course ₹2–4 lakh; chemotherapy cycles for advanced disease ₹15,000–30,000 each; pembrolizumab + lenvatinib immunotherapy ₹2–3 lakh per cycle. Lynch syndrome genetic testing for the patient ₹8,000–25,000. CION provides a written treatment plan and itemised cost estimate before treatment begins, with an EMI facility available on selected packages.

For endometrial cancer, the deciding factor is whether the hospital has a gynaecologic oncologist (a specialist who treats only women’s cancers, distinct from a general gynaecologist) and a properly resourced pathology lab for Lynch syndrome screening. A cancer-specialty hospital or network usually offers tighter oncology coordination, established gynaecologic oncology pathways, integrated genetic counselling, and survivorship services. A multi-specialty general hospital with a strong gynaecologic oncology unit and minimally invasive surgery programme can also work well. The structural fit for most women is the cancer-specialty pathway with NABH-accredited partners for surgery.

Yes. For most early-stage endometrial cancers, minimally invasive surgery — laparoscopic or robotic hysterectomy with removal of both ovaries and tubes — is the preferred approach. Compared to open surgery, minimally invasive approaches typically mean smaller scars, less pain, shorter hospital stay, and faster recovery, without compromising cancer outcomes when done by experienced surgeons. Robotic surgery has additional precision benefits in selected cases. CION coordinates minimally invasive endometrial cancer surgery through NABH-accredited partner hospitals with established gynaecologic oncology programmes.

Lynch syndrome is an inherited condition that significantly increases the risk of endometrial cancer (40–60% lifetime risk in carriers), colon cancer (60–80% lifetime risk), ovarian cancer, and several other cancers. About 3–5% of all endometrial cancers are linked to Lynch syndrome. Universal testing — meaning every endometrial cancer biopsy is screened with a pathology test called MMR immunohistochemistry — is now the recommended standard, because identifying Lynch syndrome carriers matters not only for the patient (different surveillance for other cancers, eligibility for immunotherapy) but also for blood relatives (siblings, children, parents) who may also carry the gene and benefit from early screening. CION performs MMR testing on every endometrial cancer biopsy and coordinates genetic counselling for any patient with abnormal MMR results.

In very specific circumstances, yes. For young women diagnosed with the earliest grade and stage of endometrial cancer who haven’t completed their family, an alternative to immediate hysterectomy is high-dose progestin hormone therapy with close monitoring. This approach is only appropriate for a very narrow group — grade 1 tumour, no muscle wall invasion seen on MRI, no other risk features — and the decision needs careful counselling because there’s a small risk of disease progression. After childbearing is complete, hysterectomy is recommended even if hormone therapy was successful. CION coordinates this pathway through the gynaecologic oncology partner team with reproductive endocrinology support.

Many qualified hospitals are empanelled for Aarogyasri and most major cashless insurers — but empanelment varies by centre and by procedure. Robotic surgery and immunotherapy in particular have specific scheme rules. CION Cancer Clinics is empanelled for Aarogyasri and accepts most major cashless insurance providers and TPAs. Request a written cost estimate and confirm pre-authorisation before treatment begins, especially for minimally invasive surgery and any immunotherapy.